A new US pharmacy recall includes certain compounded semaglutide and tirzepatide injections. Greenwich Rx announced the recall on 20 November 2026 because the sterility of specific products could not be assured. Some were prepared for another pharmacy, Clove Rx, so the dispensing pharmacy on the label matters too.
This is a notice about particular compounded products and lots, not a recall of every semaglutide or tirzepatide medicine. The most useful next step is an exact label check against the pharmacy’s official affected-lot list.
Which products does the recall cover?
The company announcement published by the US Food and Drug Administration (FDA) concerns specific lots of compounded sterile products dispensed nationwide between 10 August and 21 September 2026. The pharmacy’s list includes several semaglutide and tirzepatide combinations, as well as other compounded injections.
Examples of listed product names include Semaglutide/B12 Injection, Semaglutide/Glycine Injection, Semaglutide/Methylcobalamin Injection and several tirzepatide combinations. These examples are not a complete list. A medicine name alone does not establish whether an individual vial is affected.
Greenwich Rx says it is contacting affected customers by mail. People who received products through Clove Rx should check the list even if a recall letter has not arrived. The announcement does not establish a recall of products supplied outside the US.
How to check the label accurately
Keep the container and dispensing details available while comparing the label with the official list. Its filters allow readers to choose the product and whether it was dispensed through Greenwich Rx or Clove Rx. Check all of the identifying fields together:
- Full product name: include any added ingredient, such as B12, glycine or methylcobalamin.
- Strength: copy the complete concentration exactly as printed. Do not convert it into a dose or syringe units.
- Package size: compare the vial volume as well as the medicine name.
- Lot number: match every part of the code, including its final digits.
- Beyond-use date and dispensing pharmacy: compare both with the corresponding row.
A beyond-use date is not reassurance that a recalled product can still be used. The recall is the relevant safety instruction for an affected lot. Equally, a similar-looking vial or a partially matching product name is not enough to identify one. Ask the recall contact or dispensing pharmacy to resolve an unclear label.
Why a sterility concern matters
Medicines intended to be sterile can cause serious, potentially life-threatening infections if they are not sterile. Greenwich Rx says the concern followed an FDA inspection and its own evaluation. It reported no identified evidence of contamination in the recalled products and no related adverse-event reports as of the announcement.
Those statements do not remove the precautionary recall. A lack of reported harm is not proof that every vial is safe, and the notice does not say that contamination has been demonstrated in every affected product.
What does the official notice tell affected customers to do?
The notice instructs consumers and clinics with a recalled product to stop using that product immediately and discard it. It links to FDA medicine-disposal information. It also advises contacting a physician or healthcare provider about any problems that may be related to a recalled product.
For recall questions, the published contact is Sedgwick, 888-243-5547, Monday to Friday, 8 am to 5 pm US Eastern Time, or GreenwichRx6588@sedgwick.com. Ask the dispensing pharmacy or prescriber about treatment continuity and an appropriate replacement. This article does not provide a substitute medicine, dose conversion, taper or restart plan.
Suspected adverse reactions or quality problems can also be reported through FDA MedWatch. Reporting a concern does not replace medical assessment when someone is unwell.
Does this mean all GLP-1 medicines are unsafe?
No. The recall identifies a particular pharmacy’s compounded products and lots. It does not announce a class-wide withdrawal of semaglutide or tirzepatide, or a recall of every approved branded product containing either ingredient.
The FDA explains that compounded medicines are not FDA-approved: the agency does not assess their safety, effectiveness and quality before marketing in the same way as approved medicines. The FDA also has separate advice about unapproved GLP-1 drugs. That wider background should not be confused with the exact scope of this recall.
Questions worth asking the pharmacy
- Does my complete product name, concentration and lot match a recalled entry?
- Was this preparation made by Greenwich Rx, including any supplied through Clove Rx?
- What should I do if my label is incomplete or the lot number is unreadable?
- Who will coordinate replacement and any necessary discussion with my prescriber?
For other current patient-facing updates, visit Living Diabetes news. Our separate US propranolol recall article concerns a different product and a different recall; its batch details and instructions should not be applied to these injections.